Výsledky vyhledávání

Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease

Autor: Iago Rodríguez‐Lago, Urko Aguirre, Patricia Ramírez de la Piscina, Ana Muñagorri, Eva Zapata, Rebeca Higuera, Isabel Montalvo, Ainara Iriarte, María Fernández‐Calderón, Paz Arreba, Juan Carrascosa, José Luis Cabriada, Manuel Barreiro‐de Acosta

Publikováno v: United European Gastroenterology Journal. 11:9-18

Previous data support that the inflammatory process underlying ulcerative colitis (UC) and Crohn's disease (CD) can start years before the diagnosis. The aim of this study was to determine if patients with an incidental diagnosis of UC or CD demonstr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8fa05d787be3fc954b1b786a8622e0c
https://doi.org/10.1002/ueg2.12352

Zobrazit plný text záznamu

Early microscopic findings in preclinical inflammatory bowel disease

Autor: María Fernández-Calderón, Eva Zapata, Isabel Montalvo, Miguel Muñoz-Navas, Iago Rodríguez-Lago, Rebeca Higuera, Manuel Barreiro-de Acosta, Juan Carrascosa, Ainara Iriarte, Ainara Maiz, Irene Azagra, Paz Arreba, Cynthia Ramírez, Olga Merino, José Luis Cabriada

Publikováno v: Digestive and Liver Disease. 52:1467-1472

Background The immune response involved in the pathogenesis of Inflammatory Bowel Disease (IBD) may be present years before the diagnosis, but the characteristics of the disease during the preclinical period have been scarcely investigated. Aim To de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa002dabb34cec9cdaedebe15603804f
https://doi.org/10.1016/j.dld.2020.05.052

Zobrazit plný text záznamu

Ustekinumab treatment for toxic megacolon in severe colonic Crohn's disease

Autor: Martín, Irabien, Paz, Arreba, Jone, Ortiz de Zárate, Nerea, Hernández-Aretxabaleta, Saioa, de la Maza-Ortiz, Nahia, Ispizua-Madariaga, Carmen, Muñoz-Villafranca

Publikováno v: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 113(3)

Toxic megacolon is most commonly considered as a complication of inflammatory bowel disease, especially ulcerative colitis and colonic Crohn's disease to a lesser extent. It appears in the context of moderate-to-severe disease and often requires cole

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1d513ab74eac816e85dcceaf2a0b52d0
https://pubmed.ncbi.nlm.nih.gov/33244975

Zobrazit plný text záznamu

Characteristics and Progression of Preclinical Inflammatory Bowel Disease

Autor: María Fernández-Calderón, Isabel Montalvo, Iago Rodríguez-Lago, Ainara Iriarte, Isabel Portillo, Olga Merino, Rebeca Higuera, Irene Azagra, Ainara Maiz, Urko Aguirre, Juan Carrascosa, José Luis Cabriada, Eva Zapata, Paz Arreba, Miguel Muñoz-Navas, Manuel Barreiro-de Acosta

Publikováno v: Clinical Gastroenterology and Hepatology. 16:1459-1466

Background & Aims Inflammatory bowel disease (IBD) is a chronic disease usually diagnosed after the appearance of gastrointestinal symptoms. Little is known about IBD progression during its early and even preclinical phases. We aimed to determine the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b8a47603ef56b895f99fbf899d27c56
https://doi.org/10.1016/j.cgh.2017.11.006

Zobrazit plný text záznamu

P234 Association between anti-TNFα drug levels and drug-induced lupus in patients with Inflammatory Bowel Disease

Autor: M L Garcia-Vivar, M Irigoyen, A Bilbao, Gastro-Reuma, Nerea Hernandez-Aretxabaleta, C Garcia-Gomez, J Ortiz de Zárate, C Muñoz-Villafranca, Paz Arreba, U Aresti, Martin Irabien

Publikováno v: Journal of Crohn's and Colitis. 15:S281-S282

Background Drug-induced lupus (DIL) has been described as an adverse event of an immunological nature, in relation to treatment with anti-TNFα drugs. It is considered as a manifestation uncommon in patients with inflammatory bowel disease (IBD). The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d36c3966646e47a78619a350ae052d95
https://doi.org/10.1093/ecco-jcc/jjab076.360

Zobrazit plný text záznamu

Ustekinumab Treatment for Toxic Megacolon in Severe Colonic Crohn�s Disease: First Case Report

Autor: Jone Ortiz de Zarate, C Muñoz-Villafranca, Martin Irabien, Nahia Ispizua-Madariaga, Saioa de la Maza-Ortiz, Paz Arreba, Nerea Hernandez-Aretxabaleta

Publikováno v: Revista Española de Enfermedades Digestivas.

Toxic megacolon is most commonly considered as a complication of inflammatory bowel disease, especially ulcerative colitis and colonic Crohn’s disease to a lesser extent. It appears in the context of moderate-to-severe disease and often requires co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee1bad3a718dcb67428732cdcea22c5a
https://doi.org/10.17235/reed.2020.7228/2020

Zobrazit plný text záznamu

P489 Rescue treatment with original versus biosimilar infliximab in biologic-naïve patients with moderate-severe Ulcerative Colitis and corticosteroid failure

Autor: B Álvarez-Herrero, S De La Maza-Ortiz, U Aresti, J M Gómez-Zabala, Paz Arreba, M Irigoyen, P Ramírez de la Piscina, A Loizate, I Gorostiza, J Ortiz de Zárate, C Muñoz-Villafranca, M Á Ogueta

Publikováno v: Journal of Crohn's and Colitis. 15:S475-S475

Background Infliximab is effective as rescue therapy in moderate-severe Ulcerative Colitis (UC). Subsequently, a biosimilar of infliximab has been approved for the same indications, as its effectiveness is considered similar to the original inflixima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37cd9417f379fe006f59c418bd0727eb
https://doi.org/10.1093/ecco-jcc/jjab076.612

Zobrazit plný text záznamu

Evolución clínica tras la suspensión de infliximab en pacientes con colitis ulcerosa en remisión profunda

Autor: Iñigo García Kamiruaga, Jone Ortiz de Zárate, Juan Ignacio Heras Martín, Carmen Muñoz Villafranca, Maria Teresa Bravo Rodríguez, Paz Arreba González, Víctor Orive Cura, Pilar Cabezudo Gil

Publikováno v: Gastroenterología y Hepatología. 39:442-448

Resumen Introduccion Infliximab (IFX) es efectivo en la colitis ulcerosa (CU) y en obtener la curacion de la mucosa (CM). Se conoce poco el papel que juega la CM en la evolucion posterior de la enfermedad y que ocurre una vez se interrumpe el tratami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d0f88c239af4bde07522d13a38e09ee
https://doi.org/10.1016/j.gastrohep.2015.11.011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání